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Platé M, Lawson PJ, Hill MR, Quint JK, Kumari M, Laurent GJ,
Wedzicha JA, Chambers RC, Hurst JR. Impact of a functional polymor-
phism in the PAR-1 gene promoter in COPD and COPD exacerbations. Am
J Physiol Lung Cell Mol Physiol 307: L311–L316, 2014. First published June
27, 2014; doi:10.1152/ajplung.00128.2014.—Proteinase-activated recep-
tor-1 (PAR-1) plays a key role in mediating the interplay between
coagulation and inflammation in response to injury. The aim of this
study was to investigate the role of the promoter single-nucleotide
polymorphism (SNP) rs2227744GA in modulating PAR-1/F2R
gene expression in the context of chronic obstructive pulmonary
disease (COPD) and COPD exacerbations. The function of the
rs2227744GA SNP was investigated by using reporter gene assays.
The frequency of the polymorphism in the UK population was
assessed by genotyping 8,579 healthy individuals from the Whitehall
II and English Longitudinal Study of Ageing cohorts. The
rs2227744GA SNP was genotyped in a carefully phenotyped cohort
of 203 COPD cases and matched controls. The results were further
replicated in two different COPD cohorts. The minor allele of the
rs2227744GA polymorphism was found to increase F2R expression
by 2.6-fold (P  0.001). The rs2227744GA SNP was not signifi-
cantly associated with COPD, or with lung function, in all cohorts.
The minor allele of the SNP was found to be associated with
protection from frequent exacerbations (P  0.04) in the cohort of
COPD patients for which exacerbation frequency was available.
Considering exacerbations as a continuous variable, the presence of
the minor allele was associated with a significantly lower COPD
exacerbation rate (3.03 vs. 1.98 exacerbations/year, Mann-Whitney
U-test P  0.04). Taken together, these data do not support a role for
the rs2227744GA F2R polymorphism in the development of COPD
but suggest a protective role for this polymorphism from frequent
exacerbations. Studies in separate cohorts to replicate these findings
are warranted.
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INFLAMMATION OF THE LUNG PARENCHYMA and airways is a central
mechanism in the pathogenesis of obstructive lung diseases.
The nature, magnitude, and pathways responsible for the ini-
tiation and persistence of inflammation vary between diseases,
but upstream signaling responses may be activated ubiqui-
tously. One such generic pathway includes the activation of the
seven transmembrane domain G protein-coupled receptor pro-
teinase-activated receptor-1 (PAR-1) in response to the local
activation of the coagulation cascade (27). PAR-1 acts as
cellular sensor of tissue injury and plays a pivotal role in
orchestrating inflammatory and fibroproliferative responses
during both normal wound healing, and a range of pathological
contexts across all major organ systems (25). The major
activators of PAR-1 include key proteinases of the coagulation
cascade such as thrombin and factor Xa, the latter either alone
or as part of the more potent tissue factor-factor VII-factor Xa
ternary complex (6), although it is increasingly recognized that
PAR-1 can also be activated by noncoagulation proteinases,
including MMP-1 (5).
Chronic obstructive pulmonary disease (COPD) is charac-
terized by progressive airflow obstruction that is only partly
reversible, inflammation in the airways, and systemic effects or
comorbidities. The main cause in the developed world is
smoking tobacco in genetically susceptible individuals, but
other factors have also been identified (9). Approximately 1%
of COPD is associated with functional 1-antitrypsin defi-
ciency (36), which provides the best model of genetic suscep-
tibility to COPD. Current evidence, including data obtained in
genomewide association studies (GWAS), shows that suscep-
tibility is complex and may relate in part to epigenetic phe-
nomena (33). COPD is a heterogeneous condition comprising
many important clinical phenotypes that may have a different
natural history or treatment response. Illustrating the potential
importance of PAR-1 signaling in COPD, we have previously
shown that PAR-1 knockout mice develop emphysema (3) but
are protected from chronic bronchitis, supporting the notion
that PAR-1 signaling pathways may influence clinical pheno-
type in this disease context. Episodes of acute functional
deterioration, known as exacerbations, punctuate the natural
history of COPD and account for most of the morbidity,
mortality, and health care costs associated with this condition
(12). There are several potential triggers, and exacerbations
have been associated with airway infection, exposure to pol-
lutants, or stimuli that affect expiratory airflow limitation (19).
Some patients appear intrinsically more susceptible to exacer-
bations than others (18), and an important phenotype in COPD
is the “frequent exacerbator” (35). The role of PAR-1 in this
group of patients has not been previously examined, but COPD
is associated with a hypercoaguable state (2, 20, 39). More-
over, an association has recently been demonstrated between
thrombocytosis and significantly increased 1-year mortality
following admission with acute COPD exacerbation, and
PAR-1 represents the major thrombin receptor on human platelets
(17). Interestingly, the common polymorphism rs2227744GA in
F2R (PAR-1 coding gene) promoter has been associated with
inflammation and myocardial infarction (MI) in two Swedish
cohorts (15). We now hypothesize that PAR-1 signaling influ-
ences susceptibility to COPD and the development of specific
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clinically relevant phenotypes, such as the frequent exacerba-
tor. To address this hypothesis, we assessed the impact of the
rs2227744GA variant on F2R promoter activity using re-
porter gene assay experiments. We then assessed the polymor-
phism frequency in the general UK population, genotyping
8,579 healthy individuals from the English Longitudinal Study
of Ageing (ELSA) and Whitehall II cohorts. Finally, we
explored whether this PAR-1 polymorphism predisposes to
susceptibility to COPD and/or frequent COPD exacerbations.
MATERIALS AND METHODS
Polymorphism Characterization
Plasmid preparation. A 5.2-kb F2R promoter was excised from a
HBAC clone (CTD-2384B11, Life Technologies, Carlsbad, CA) and
inserted into pGL3 Basic Vector (Promega, Madison, WI) to produce
the pGL3-F2R-wt plasmid. The presence and accuracy of the insert
was confirmed by restriction mapping and sequencing by using the
ABI PRISM BigDye Terminator v3.1 Cycle sequencing kit (Applied
Biosystems, Foster City, CA), following the manufacturer’s instruc-
tions. The rs2227744A allele was introduced in the wild-type plasmid
by site-directed mutagenesis by using the QuickChange II XL Site-
Directed Mutagenesis Kit (Stratagene, La Jolla, CA) as indicated by
the manufacturer, producing the pGL3-F2R-rs227744A plasmid.
Large-scale recovery of plasmid DNA to use for transient transfec-
tions was performed by using the EndoFree Plasmid MAXI Kit
(QIAGEN, Hilden, Germany), according to the manufacturer’s in-
structions.
Cell culture and transfections. HeLa (human cervix carcinoma cell
line) cells were grown at 37°C in a humidified atmosphere of 5% CO2
and 95% air in Dulbecco’s modified Eagle’s medium (DMEM, Life
Technologies) supplemented with 10% fetal bovine serum (Life
Technologies), 2 mM glutamine (Life Technologies), and antibiotics
(100 IU/ml penicillin and 100 g/ml streptomycin, Life Technolo-
gies). When 50% confluent, cells were transfected with 1 g of the
wild-type plasmid, the mutant plasmid, or the empty pGL3 vector plus
0.05 g pRL-TK Renilla vector as an internal control to correct for
differences in transfection efficiency and cell viability. The transfec-
tion was accomplished with the LID vector transfection system as
described (1).
Firefly luciferase and Renilla luciferase assays. Transcriptional
activity was assayed by measuring luciferase activity. The activities of
firefly and Renilla luciferase were measured 18 h after transfection by
using the Dual-Luciferase Reporter Assay System (Promega). All
transfections were performed in seven replicates and each construct
was tested in three independent experiments using two different
batches of plasmid preparation. The luciferase activity was measured
with the TROPIX TR717 Microplate Luminometer (PE Applied
Biosystems). For each construct, the values of firefly luciferase
activity in different experiments were normalized against the corre-
sponding values of Renilla luciferase (all expressed as relative lumi-
nescent units). Normalization was performed for each sample before
comparing test groups.
Subjects
Control subjects. A total of 8,579 control subjects were studied in
the Whitehall II and ELSA cohorts, which have been previously
described (23, 38). Individuals with lung disease were excluded from
the control cohorts for the purpose of this study. Among these, 609
age-, sex-, and smoke-matched controls were selected randomly for
the case/control association analyses with the COPD cohort. Current
and former smokers were aggregated in the single category of smok-
ers. The remaining 1,133 Whitehall II and 1,094 ELSA smoker
controls were included in the case/control association analyses with
the Whitehall II and ELSA COPD cohorts, respectively.
Patients. Two hundred and three COPD patients from the London
COPD cohort were recruited and monitored as previously described
(11). COPD was defined by a postbronchodilator forced expiratory
volume in 1 s (FEV1) of 80% predicted, FEV1/forced vital capacity
(FVC) 0.7, and 2-agonist reversibility on FEV1 of 15% and/or
200 ml. Patients were excluded if they had a history of other signif-
icant respiratory diseases, for example asthma. The patients com-
pleted daily diary cards recording any increase in daily respiratory
symptoms (11), allowing us to prospectively and accurately record
their exacerbations as previously described (32). The diary card
definition of exacerbation has been validated against changes in
quality of life (35), inflammatory markers (4), and FEV1 decline (11).
This allowed us to classify patients as frequent (3 exacerbations in
the previous year) and infrequent (3 exacerbations in the previous
year) exacerbators. Exacerbation definitions based on symptom crite-
ria capture all events and therefore a frequent exacerbator is defined as
3 exacerbations in the previous year, rather than 2, which would
apply in studies using a health-care utilization approach.
COPD patients in the Whitehall II (318) and ELSA (364)
cohorts were defined at baseline as those who had smoked, who did
not report a diagnosis of asthma, and had both FEV1 80% and
FEV1/FVC 0.7.
This study was conducted in accordance with the amended Decla-
ration of Helsinki. Local institutional review boards or independent
ethics committees approved the protocol, and written, informed con-
sent was obtained from all patients. London COPD cohort: Royal Free
Hospital; REC reference number 05/Q0501/126. ELSA: IRB00002308;
MREC reference number MREC/04/006. Whitehall II: Joint Univer-
sity College London/University College London Hospital Committees
on the Ethics of Human Research (Committee Alpha).
Polymorphism Genotyping
Genotyping of the Whitehall II and ELSA cohorts was performed
by KBiosciences by using the KASPar assay (LGC, Middlesex, UK),
based on the Kompetitive Allele Specific PCR (KASP) technology.
Genotyping error rates were examined from a repeat of 10% of
samples in ELSA and 5% of samples in Whitehall II.
Within the COPD study, the rs2227744GA single-nucleotide
polymorphism (SNP) was genotyped by TaqMan assay (Applied
Biosystems). In the COPD cohort random duplicated testing of 5% of
the samples was performed and 10% of the samples genotypes were
confirmed by direct sequencing.
In all cases the error rate was found to be 1%.
Statistical Analyses
In reporter gene assay experiments, differences between plasmids
were examined by univariate analysis. Reproducibility across repeat
experiments was investigated by including the replicate experiments
as a fixed factor.
For phenotypic data, categorical data were tested for difference
between cases and controls by means of a 2 test and continuous data
were tested by the two-tailed Student t-test.
For genotypic data, all procedures were performed with the soft-
ware package PLINK v1.07 (31). Hardy-Weinberg equilibrium was
tested by the exact test described by Wigginton et al. (41) and
implemented in the PLINK software. For comparison between cases
with age-, sex-, and smoke-matched controls, a standard case-control
analysis using allelic 2 test to provide asymptotic P values, odds
ratios, and 95% confidence intervals for the minor allele was used. For
comparison between frequent and infrequent exacerbators, given the
small size of the cohort, a Fisher’s exact test was used (13). Logistic
regression with correction for age and sex was used for the Whitehall
II and ELSA COPD cohorts. For lung function analyses a Wald test
was used. Values of P  0.05 were considered to indicate statistical
significance. The Mann-Whitney U-test was used to examine the
relationship between allele frequencies and number of exacerbations.
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RESULTS
F2R Haplotypes and Promoter Activity
To determine whether the SNP rs2227744GA is func-
tional, the rs2227744A minor allele was inserted into a plasmid
containing the PAR-1 promoter upstream of the luciferase gene
and the promoter activity was assessed in transient transfection
experiments using HeLa cells. These studies revealed that the
presence of the minor allele A of the SNP rs2227744GA
confers 2.6 	 0.31-fold higher basal activity compared with
the wild-type allele (P  0.001), with no further increase seen
following stimulation with TNF (10 ng/ml; data not shown).
Phenotypic and Genotypic Characteristics of the Control UK
Cohort
The frequency of the rs2227744GA SNP was assessed in
8,579 individuals with no reported respiratory disease, who
participated in the ELSA or Whitehall II study, as a represen-
tative sample of the UK Caucasian healthy population. The
frequency of the minor allele was found to be 0.45. The SNP
was in Hardy-Weinberg equilibrium.
Phenotypic and Genotypic Characteristics of the COPD
Cohort
The characteristics of the COPD patients and age-, sex-, and
smoke-matched healthy control subjects selected from ELSA
and Whitehall II are reported in Table 1 and demonstrate that
the groups were well matched and that the COPD patients had
obstructive lung function typical of that condition. The char-
acteristics of the ELSA and Whitehall II COPD cases and
controls are summarized in Table 2.
The frequency of the rs2227744GA polymorphism was
assessed in the control and COPD subjects. Genotype frequen-
cies were analyzed to verify whether their distribution fit
expectations under the Hardy-Weinberg equilibrium. This SNP
did not show a statistically significant deviation from the
equilibrium in cases or controls (or both) (data not shown).
Allelic 2 analyses on cases and controls revealed that the SNP
was not associated with the development of COPD. We next
assessed whether this SNP was associated with clinical phe-
notype by comparing frequent and infrequent exacerbators
(Table 1). Comparing the frequency of the SNP by exacerba-
tion frequency using Fisher’s exact test, we found that the
rs2227744A allele was less common in the frequent than the
infrequent exacerbator phenotype (Table 3). Reflecting this,
and considering exacerbations as a continuous variable, the
presence of the minor allele of the SNP was associated with a
significantly lower exacerbation rate (Mann-Whitney U-test,
1.98 vs. 3.03 exacerbations/year, P  0.04). The lack of
association of this SNP with the development of COPD was
replicated in two additional COPD cohorts identified within the
Whitehall II and ELSA participants. The SNP was in Hardy-
Weinberg equilibrium in both populations (data not shown).
Logistic regression analyses confirmed the lack of association
between the SNP and COPD, before (data not shown) and after
correction for age and sex (Table 3). Relationship between the
SNP genotypes and lung function was investigated in all the
cohorts and no significant association was found (Table 4).
DISCUSSION
PAR-1 plays a critical role in mediating the interplay be-
tween coagulation and inflammation and represents an inter-
esting candidate gene in the setting of COPD, a condition in
which both pulmonary and systemic coagulation and inflam-
mation are increased (7, 25). PAR-1 polymorphisms have been
investigated in other disease contexts and positive associations
Table 1. Clinical characteristics of the COPD patients and matched healthy controls from ELSA and Whitehall II
COPD (n  203) Controls (n  609)
Characteristics IE (n  136) FE (n  67) P Value IE vs. FE All All P Value COPD vs. Control
Age, yr 71.4 	 8.9 70.7 	 8.7 0.61 71.2 	 8.8 71.2 	 8.8
Male 84 (62%) 36 (54%) 0.05 120 (59%) 360 (59%)
Ever smoked, % 100 100 100 100
FEV1, liters 1.22 	 0.54 1.13 	 0.43 0.17 1.19 	 0.50 2.24 	 0.72 0.001
FEV1, % predicted 50 	 20 48 	 17 0.49 49 	 19 92 	 21 0.001
FVC, liters 2.58 	 0.97 2.39 	 0.90 0.17 2.52 	 0.95 2.97 	 0.99 0.001
FEV1/FVC 0.48 	 0.14 0.49 	 0.15 0.76 0.48 	 0.14 0.76
	0.08 0.001
Data are presented as means 	 SD or number with % in parentheses. COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in
1 s; FVC, forced vital capacity; IE, infrequent exacerbators; FE, frequent exacerbators.
Table 2. Clinical characteristics of the COPD patients and healthy controls from ELSA and Whitehall II
WHII ELSA
Characteristics Cases (n  318) Controls (n  1133) P Value Cases (n  364) Controls (n  1094) P Value
Age, yr 45.73 	 6.1 43.43 	 5.7 0.001 71.40 	 9.6 66.03 	 8.44 0.001
Male 199 (63%) 860 (76%) 0.001 207 (57%) 510 (47%) 0.001
Ever smoked, % 100 100 100 100
FEV1, liters 2.04 	 0.68 3.05 	 0.67 0.001 1.38 	 0.60 2.46 	 0.77 0.001
FEV1, % predicted 59.16 	 14.83 84.52 	 11.79 0.001 56.16 	 18.56 99.39 	 43.43 0.001
FVC, liters 3.49 	 0.88 3.96 	 0.77 0.001 2.62 	 0.97 3.20 	 1.06 0.001
FEV1/FVC 0.58 	 0.11 0.77 	 0.06 0.001 0.53 	 0.14 0.78 	 0.08 0.001
Data are presented as means 	 SD or number with % in parentheses. WHII, Whitehall II.
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have been found for venous thromboembolism (37), coronary
heart disease (28), liver fibrosis (24), and MI (15). Interest-
ingly, in the context of heart disease, PAR-1 variants, including
the rs2227744A allele located in the F2R promoter, have been
shown to associate with increased inflammation and MI (15).
Despite this, to the best of our knowledge, the function of the
rs2227744GA variant is unknown and its involvement in
COPD has not been investigated. The aim of this study was to
determine whether this genetic variant may track with COPD
and COPD exacerbation frequency, based on our previous data
in mice suggesting that F2R may affect the development of key
COPD phenotypes (3).
Using reporter gene assays and a 5.2-kb promoter construct
transfected into HeLa cells, we show that the rs2227744A
minor allele increases PAR-1 expression by almost threefold.
In silico analysis using common free-access online tools sug-
gests that this SNP is not directly located in a binding site for
transcription factors and that the minor allele does not intro-
duce a new transcription factor binding site. However, this
SNP is located within a DNAse I hypersensitivity region
upstream of the main transcription factor binding cluster for
this gene. This raises the possibility that this SNP may promote
PAR-1 gene expression by influencing the availability of bind-
ing sites at nearby transcription factor binding site locations.
Given the role of PAR-1 in influencing multiple downstream
inflammatory pathways, the observation that this polymor-
phism is functional and impacts on PAR-1 gene transcription
may explain the previous report that associated the rs2227744A
allele with higher inflammation in subjects at risk of MI (15).
In contrast, our data show that there is no association between
this SNP and the development of COPD in three large Cauca-
sian cohorts. Similarly, the SNP was found not to be associated
with lung function in all the cohorts. However, comparing
frequent and infrequent exacerbators in our cohort of COPD
patients, we found that the minor allele of the SNP associated
with fewer exacerbations. To the best of our knowledge, this is
the first study to investigate the impact of a functional poly-
morphism in the PAR-1 promoter on the development of
COPD and the determination of COPD phenotypes.
Although we fully acknowledge that our COPD cohort is
small, our study was performed on carefully phenotyped pa-
tients who were monitored on a daily basis over many years
with exacerbations identified by use of previously described
and validated criteria of respiratory symptom increase (11).
Traditionally, the view has been that frequent COPD exacer-
bator status may be associated with increased inflammatory
responses, and it is known that both IL6 and fibrinogen levels
are increased at exacerbation (40). On the basis of our data, it
is therefore tempting to speculate that, in COPD, higher levels
of PAR-1 gene expression above a certain threshold contrib-
uted, at least in part, by the rs2227744A allele might support an
appropriate PAR-1-mediated inflammatory response that leads
to early resolution of disease and resistance to COPD exacer-
bation. In contrast, PAR-1 expression levels that fail to lead to
an appropriate PAR-1-mediated inflammatory response may
support the continuation of chronic inflammation. It is also
possible that the absence of an appropriate PAR-1-mediated
inflammatory response in response to a stimulus predisposes to
recurrent infections that characterize the frequent COPD exac-
erbator phenotype. Inflammation is particularly important at
exacerbation of COPD, when there is also evidence of in-
creased activation of coagulation (40). This may be particularly
important in relation to the interplay between COPD, COPD
exacerbations, and cardiovascular risk (29).
Studies in murine models focusing on the role of PAR-1 in
the context of bacterial infection have revealed that the role of
this receptor during infection is highly context and time de-
pendent and both can be advantageous by influencing a robust
inflammatory response but also may be deleterious and pro-
mote bystander tissue damage (1, 21, 22, 26, 34). This may in
part explain the paradoxical role of the SNP in the context of
COPD reported in the present article in that the function of the
rs2227744 SNP (i.e., higher PAR-1 expression) only manifests
itself during episodes of exacerbation since the advantageous
proinflammatory response could aid the control of bacterial
infection (a major cause of COPD exacerbation).
Table 3. PAR-1 Polymorphisms and susceptibility to COPD and exacerbations
Cases Controls Minor Allele Frequency Cases Minor Allele Frequency Controls P Value OR (95% CI)
London cohort 203 609 0.44 0.46 0.34 0.90 (0.71–1.12)
WHII 318 1133 0.48 0.45 0.18 1.13 (0.94–1.36)
ELSA 364 1094 0.47 0.46 0.58 1.05 (0.88–1.25)
FE IE Minor Allele Frequency FE Minor Allele Frequency IE
FE vs. IE 67 136 0.37 0.46 0.04* 0.64 (0.42–0.98)
Analysis of rs2227744GA allele frequency differences in COPD. OR, odds ratio; CI, confidence interval. Significant results are indicated with an asterisk.
Differences between cases and controls in the London cohort were performed by means of an allelic 2 test. Differences between cases and controls in the
Whitehall II and ELSA cohorts were performed by logistic regression with correction for age and sex. Differences between frequent exacerbators (FE) and
infrequent exacerbators (IE) were tested with a Fisher’s exact test.
Table 4. PAR-1 and lung function in COPD
GG GA AA P Value
London cohort
FEV1, liters 1.10 1.24 1.20 0.25
FEV1, % predicted 49 50 50 0.75
FVC, liters 2.32 2.63 2.53 0.19
ELSA cohort
FEV1, liters 1.38 1.37 1.39 0.90
FEV1, % predicted 56 56 55 0.81
FVC, liters 2.70 2.59 2.60 0.45
Whitehall II cohort
FEV1, liters 2.15 1.97 2.10 0.60
FEV1, % predicted 61 58 61 0.98
FVC, liters 3.67 3.40 3.51 0.25
Analysis of rs2227744GA and lung function relationship in COPD.
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Several GWAS have now been conducted in COPD and
several genes have been found to be associated with the
development of this condition, the most common and strongly
associated being HHIP (hedgehog-interacting protein) (30),
CHRNA3 (cholinergic receptor, nicotinic, alpha 3) (30), IREB2
(iron responsive element binding protein 2) (10), and FAM13A
(family with sequence similarity 13, member A) (8). CHRNA3
has been demonstrated to be associated with smoking intensity
(30) and all show an association with FEV1/FVC (16, 30) but,
to the best of our knowledge, there are no studies investigating
associations with exacerbation frequency or other key pheno-
types in COPD. In studies like the one reported here, where the
frequency of the rs2227744A allele in infrequent exacerbators
was found to be similar to that observed in the general
population (Whitehall II and ELSA healthy controls), and the
effect of the SNP on a subgroup of cases was diluted and
masked, a comparison between all COPD cases (including both
frequent and infrequent exacerbators) and healthy controls
would potentially fail to show an association between PAR-1
and susceptibility to COPD. On the contrary, highly defined
cohorts such as ours may have lower statistical power, but the
level of phenotypic characterization achieved is higher than
that of large cohorts, allowing the investigation of associations
with carefully defined subgroups and the detection of the effect
of genes with small effects only on a particular phenotype.
There is increasing evidence that the frequent exacerbator
represents an independent phenotype (18), but despite indica-
tion of familial aggregation (14), studies examining genetic
determinants of exacerbation frequency remain limited. This
reflects a need for the collection of large cohorts with the same
degree of careful phenotyping as exemplified by our cohort. It
is clear that this will require a major multicenter, collaborative
effort with highly engaged patients.
This study has some limitations, due to the degree of
characterization required to properly estimate the exacerbation
frequency. First, the number of cases for which obtaining the
exacerbation frequency was possible is small. This negatively
affects the power of the analyses. Second, the analyses regard-
ing the association of the SNP with the exacerbation frequency
need replication but this cannot at present be achieved, owing
to the lack of a similarly characterized cohort.
CONCLUSION
In conclusion, although this study demonstrates a lack of
correlation between a functional PAR-1 polymorphism and
susceptibility to COPD in three different UK cohorts, this is the
first report suggesting that the rs2227744A allele is associated
with reduced susceptibility to frequent exacerbation. Although
the mechanism by which this polymorphism may potentially
influence this important clinical phenotype remains at present
unknown, we hypothesize that PAR-1 signaling and in partic-
ular its role in modulating inflammatory responses may play an
important role in the determination of disease phenotype, a
little-studied and evolving field for which our report provides
a new model. We believe that our data further add patient-
based evidence to our current understanding of the potential
role of pathological coagulation signaling responses in promot-
ing inflammatory and potentially remodeling pathways in re-
sponse to chronic lung injury. Future studies aimed at repli-
cating these findings and at further defining the relationship
between coagulation signaling events and inflammation in
these disease contexts are urgently required and may shed
important light on the pathomechanisms underlying the devel-
opment and progression of these conditions.
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